AZD 6244 – 25 mg

Brand:
Cayman
CAS:
606143-52-6
Storage:
-20
UN-No:
Non-Hazardous - /

MEK kinases are central components of diverse intracellular signaling pathways. MEK1 and MEK2 specifically act downstream of growth factor receptors and the proto-oncogenes Ras and Raf to activate ERK1 and ERK2, often leading to an increase in cell proliferation.{24267} AZD 6244 is a potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14 and 530 nM, respectively).{24156,24266,24267} It weakly inhibits the EGF receptor (IC50 = 7.0 µM) and has no effect on a large panel of other kinases.{24156} AZD 6244 suppresses the growth of tumors displaying high levels of phosphorylated MEK1/2 or ERK1/2.{24266,24267} In addition to suppressing growth, it induces apoptosis and differentiation within tumors.{24265} AZD 6244 has potential, alone or in combination therapy, for promoting tumor regression in various forms of cancer, including those involving mutations of the proto-oncogenes Ras and Raf.{24269,24268}  

 

Available on backorder

SKU: 11599 - 25 mg Category:

Description

A potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14-99 and 530 nM, respectively); weakly inhibits EGFR (IC50 = 7.0 µM) and has no effect on a large panel of other kinases; suppresses growth and induces apoptosis and differentiation within tumors


Formal name: 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide

Synonyms:  ARRY-142886|CL 1,040|NSC 741O78|Selumetinib

Molecular weight: 457.7

CAS: 606143-52-6

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|RAS/RAF/MEK/ERK/MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|ERK/MAPK Signaling